Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) are two fatal neurodegenerative disorders characterized by the presence of insoluble aggregates of TAR DNA-binding protein of 43 kDa (TDP-43) in affected brain regions.^[@ref1],[@ref2]^ To date, most of the disease-causing mutations in TDP-43 occur in the C-terminal prion-like domain (PrLD).^[@ref3]^ PrLDs are intrinsically disordered regions that can switch from unfolded states to self-templating fibril forms such as the amyloid-like cross-β fibrils.^[@ref3]−[@ref7]^ The majority of TDP-43 aggregates in ALS/FTLD-U patients have the appearance of granular filaments, but a subset have amyloid-like qualities.^[@ref8]−[@ref11]^ Full-length TDP-43 forms granulo-filamentous aggregates *in vitro* that can transition into thread-like fibrils.^[@ref4],[@ref12],[@ref13]^ This transition is promoted by certain disease-linked mutations in the PrLD, including Q331K.^[@ref12]^ An emerging hypothesis is that the PrLD of TDP-43 may drive the protein aggregation observed in disease.^[@ref12]^

PrLDs have also been implicated in liquid--liquid phase separation (LLPS), a process by which proteins condense into reversible liquid droplets.^[@ref14]−[@ref16]^ Of interest are the ALS-linked proteins hnRNPA1, FUS, and TDP-43 which undergo LLPS *in vitro*.^[@ref4],[@ref16]−[@ref20]^ We uncovered that the biopolymer poly(ADP-ribose) (PAR) potently promotes TDP-43 LLPS *in vitro*([@ref20]) and that PAR is elevated in ALS motor neuron nuclei.^[@ref21]^ PAR is generated by poly(ADP-ribose) polymerases (PARPs),^[@ref22]^ and inhibitors of various PARPs (PARP-1, PARP-2, PARP-5a, and PARP-5b) mitigate cytoplasmic aggregation of TDP-43 and TDP-43-associated toxicity to primary neurons and in *Drosophila*.^[@ref20],[@ref21]^ These findings raised the possibility that PAR may directly regulate TDP-43 aggregation.

To determine if PAR could impact TDP-43 aggregation, we purified full-length human TDP-43 with a His~6~-SUMO solubility tag^[@ref23]^ ([Figures S1A and S2A](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.8b00910/suppl_file/bi8b00910_si_001.pdf)). At physiological concentrations of TDP-43 protein,^[@ref24]^ cleavage of the His~6~-SUMO tag with ubiquitin-like specific protease (Ulp1) induced TDP-43 aggregation over a 200 min period ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A). The addition of PAR to His~6~-SUMO-TDP-43-WT significantly reduced TDP-43-WT aggregation ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A, [Figure S2B,C](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.8b00910/suppl_file/bi8b00910_si_001.pdf)), while mono(ADP-ribose) had no effect ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B). Our previous studies established that LLPS of TDP-43 can occur in the presence of a crowding reagent and is promoted by PAR.^[@ref20]^ We examined TDP-43-WT by differential interference contrast (DIC) microscopy; before cleavage with and without PAR, the protein remained diffuse and did not form any visible micron-sized aggregates ([Figure S3A](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.8b00910/suppl_file/bi8b00910_si_001.pdf)). However, 30 min after Ulp-1 cleavage, we observed the formation of spherical droplets that appeared to coalesce into solid structures after a further 30 min ([Figure S3B](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.8b00910/suppl_file/bi8b00910_si_001.pdf)). Our present data indicate that under conditions that lack a crowding reagent, PAR reduces filamentous aggregation of TDP-43.

![PAR inhibits TDP-43 aggregation. (A) Ulp1-cleavage of His~6~-SUMO-TDP-43-WT increased optical density (OD). Co-incubation with 6 μM PAR reduced the optical density of TDP-43-WT. (B) Mono(ADP-ribose) (mADPr, 6 μM) had no effect on the optical density of TDP-43-WT.](bi8b00910_0001){#fig1}

The nuclear-localization sequence (NLS) of TDP-43 is a region of intrinsic disorder^[@ref25]^ ([Figure S1B](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.8b00910/suppl_file/bi8b00910_si_001.pdf)) and is critical for physically binding to PAR and as well as LLPS of TDP-43 *in vitro*.^[@ref20]^ In contrast to cleaved His~6~-SUMO-TDP-43-WT, cleaved His~6~-SUMO-TDP-43-ΔPAR-binding motif (PBM) ([Figure S4A](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.8b00910/suppl_file/bi8b00910_si_001.pdf)) exhibited decelerated aggregation kinetics ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A) and took over 18 h to aggregate ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B). The addition of PAR had no effect on the aggregation of TDP-43-ΔPBM ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B and [Figure S4B](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.8b00910/suppl_file/bi8b00910_si_001.pdf)). Examination of TDP-43-ΔPBM before cleavage revealed no preformed micron-sized aggregates ([Figure S3A](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.8b00910/suppl_file/bi8b00910_si_001.pdf)). Thus, the N-terminal region of TDP-43, and specifically the PBMs, enables rapid aggregation of TDP-43, and PAR engages PBMs within the NLS to reduce TDP-43 aggregation.

![PAR-binding motifs enable rapid TDP-43 aggregation. (A) Compared to TDP-43-WT, the TDP-43-ΔPAR-binding motif (PBM) did not aggregate in the same time frame. (B) TDP-43-ΔPBM aggregated over 54 h. PAR (6 μM) had no effect on the optical density of TDP-43-ΔPBM.](bi8b00910_0002){#fig2}

Transmission electron microscopy (TEM) revealed that cleavage of the His~6~-SUMO tag from both TDP-43-WT and TDP-43-ΔPBM led to the formation of granulo-filamentous aggregates ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A), consistent with previous TEM studies and of TDP-43 aggregates in human tissue.^[@ref8],[@ref10],[@ref12]^ PAR did not drastically alter the structure of the TDP-43-WT or TDP-43-ΔPBM aggregates ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A). However, PAR significantly reduced the overall size of the TDP-43-WT aggregates, while having no effect on the size of the TDP-43-ΔPBM aggregates ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B). Indeed, PAR promoted retention of TDP-43-WT in the supernatant fraction after low-speed centrifugation ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C and [Figure S5](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.8b00910/suppl_file/bi8b00910_si_001.pdf)). Thus, we propose that PAR reduces granulo-filamentous aggregation of TDP-43 via an interaction with PBMs embedded within the NLS.

![PAR reduces TDP-43 aggregation. (A) Ulp1 cleavage of HIS~6~-SUMO-TDP-43-WT and HIS~6~-SUMO-TDP-43-ΔPBM led to granulo-filamentous aggregation (hatched boxes). PAR (6 μM) reduced aggregate size of TDP-43-WT and had no effect on TDP-43-ΔPBM (hatched boxes). (B) Quantification of aggregate size. Mean (±SD), one-way ANOVA (*P* \< 0.0001), and Kruskal--Wallis test. (C) PAR (6 μM) reduced the amount of TDP-43-WT in the pellet fraction at 400*g* ([Figure S5](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.8b00910/suppl_file/bi8b00910_si_001.pdf)). Mean (±SD), two-way ANOVA, and Tukey's test.](bi8b00910_0003){#fig3}

In ALS and FTLD-U, splicing defects and proteolytic cleavage can elicit formation of TDP-43 C-terminal fragments that contain the PrLD.^[@ref26]−[@ref28]^ As the C-terminal fragments of TDP-43 either contain a partial PAR-binding region (TDP-43-C35) or lack the PAR-binding region (TDP-43-C25) ([Figure S1A](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.8b00910/suppl_file/bi8b00910_si_001.pdf)), we examined the aggregation kinetics of these two C-terminal fragments. Strikingly, the ability of TDP-43-C35 and TDP-43-C25 to form turbid aggregates was, like TDP-43-ΔPBM, reduced compared to TDP-43-WT ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A). Examination by TEM revealed that TDP-43-C35 formed granulo-filamentous aggregates, whereas TDP-43-C25 formed granulo-filamentous aggregates and thread-like fibrils ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B). The TDP-43-C25 aggregates were unreactive to the amyloid diagnostic dye Thioflavin T ([Figure S6](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.8b00910/suppl_file/bi8b00910_si_001.pdf)). Combined, these data reveal that the N-terminal portion of TDP-43 contributes to granulo-filamentous aggregation and antagonizes the transition into thread-like oligomers.

![C-terminal fragments of TDP-43 have altered aggregation properties. (A) The increase in optical density of TDP-43-C35 and TDP-43-C25 was reduced compared to TDP-43-WT. (B) TDP-43-WT, TDP-43-C35, and TDP-43-C25 formed granulo-filamentous protein aggregates (black arrows). TDP-43-C25 also formed thread-like aggregates (white arrows).](bi8b00910_0004){#fig4}

Here, we show that N-terminal portions of TDP-43 contribute to granulo-filamentous aggregation. Our data indicate that PAR interacts with PBMs embedded within the NLS of TDP-43 to reduce granulo-filamentous aggregation. Defining the mechanism by which PAR binding reduces TDP-43 aggregation will require further study. Regions within the N-terminal domain of TDP-43 regulate self-oligomerization.^[@ref25],[@ref29]−[@ref32]^Thus, PAR-binding to the NLS adjacent to the N-terminal domain may physically block interactions that contribute toward aggregation. In disease, TDP-43 aggregates appear to be predominantly granulo-filamentous. Thus, agents that antagonize contributions from the N-terminal region of TDP-43 could have therapeutic utility. However, as oligomerization is essential for TDP-43 function,^[@ref25],[@ref29]−[@ref32]^ agents that prevent this functional oligomerization could be detrimental. Understanding under what circumstances functional versus toxic TDP-43 assemblies form,^[@ref33]^ how they differ, and how they are resolved will help develop therapeutic strategies to selectively target toxic assemblies.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acs.biochem.8b00910](http://pubs.acs.org/doi/abs/10.1021/acs.biochem.8b00910).TDP-43 protein domains, protein purification analysis, turbidity assay, analysis of the sedimentation assay, and detailed materials and methods ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.8b00910/suppl_file/bi8b00910_si_001.pdf))
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